PBA
KLRS

Paradigm Biocapital Advisors’s Kalaris Therapeutics KLRS Stock Holding History

Paradigm Biocapital Advisors’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.04M Hold
700,000
– – 0.08% 35
2025
Q4 		$5.91M Buy
+700,000
New +$4.48M 0.15% 30

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Paradigm Biocapital Advisors's KLRS Position: Q1 2026 in Review

Paradigm Biocapital Advisors held its Kalaris Therapeutics (KLRS) position steady in Q1 2026 at 700,000 shares worth $4.04M. The position accounts for 0.08% of the portfolio, ranked #35.

Paradigm Biocapital Advisors first reported a position in KLRS in Q4 2025 and has held it in 2 quarters since. The position peaked at $5.91M in Q4 2025. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Paradigm Biocapital Advisors held 700,000 shares of Kalaris Therapeutics worth $4.04M as of Q1 2026.
  • Paradigm Biocapital Advisors left its Kalaris Therapeutics share count unchanged in Q1 2026.
  • Kalaris Therapeutics made up 0.08% of Paradigm Biocapital Advisors's portfolio in Q1 2026, its #35 holding.
  • Paradigm Biocapital Advisors first reported a position in Kalaris Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Paradigm Biocapital Advisors's Kalaris Therapeutics position peaked at $5.91M in Q4 2025.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.